Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib plus low-dose radiotherapy for newly diagnosed early-stage marginal zone lymphoma
ChiCTR2600133509Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in marginal zone B-cell lymphoma (MZL), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Complete remission rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on ChiCTR2600133509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133509.